Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM GLEZEN and PEDRO PIEDRA.
Connection Strength
2.415
-
Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010 Dec 01; 202(11):1626-33.
Score: 0.393
-
Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep; 120(3):e553-64.
Score: 0.315
-
Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005 Sep; 116(3):e397-407.
Score: 0.275
-
Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18; 23(13):1540-8.
Score: 0.265
-
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003 Jul 28; 21(24):3479-82.
Score: 0.238
-
Influenza virus infections in infants. Pediatr Infect Dis J. 1997 Nov; 16(11):1065-8.
Score: 0.160
-
Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illness. J Clin Microbiol. 2012 Feb; 50(2):506-8.
Score: 0.106
-
Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May; 27(5):444-52.
Score: 0.083
-
Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007 May 16; 25(20):4038-45.
Score: 0.076
-
Safety of cold-adapted live influenza vaccine. Pediatr Infect Dis J. 2004 Jun; 23(6):593-4; author reply 594.
Score: 0.063
-
Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan; 158(1):65-73.
Score: 0.061
-
Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003 Aug 15; 158(4):305-11.
Score: 0.060
-
Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine. 2003 Jul 28; 21(24):3465-7.
Score: 0.059
-
HLA-restricted CD8+ cytotoxic T lymphocyte, interferon-gamma, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J Infect Dis. 2001 Mar 01; 183(5):687-96.
Score: 0.050
-
Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000 Jan 26; 283(4):499-505.
Score: 0.047
-
Maternal immunization against viral disease. Vaccine. 1998 Aug-Sep; 16(14-15):1456-63.
Score: 0.042
-
Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine. 1995 Aug; 13(12):1095-101.
Score: 0.034
-
Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine. 1993; 11(7):718-24.
Score: 0.029
-
Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol. 1991 Feb 01; 133(3):296-304.
Score: 0.025
-
Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect. 2005 May; 50(4):322-30.
Score: 0.017
-
Dual respiratory virus infections. Clin Infect Dis. 1997 Dec; 25(6):1421-9.
Score: 0.010
-
Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States. Clin Diagn Lab Immunol. 1996 Jul; 3(4):477-9.
Score: 0.009